Predictors of long-term durable response in de novo HER2-positive metastatic breast cancer and the real-world treatment experience at two institutions

[1]  W. Woodward,et al.  NRG-BR002: A phase IIR/III trial of standard of care systemic therapy with or without stereotactic body radiotherapy (SBRT) and/or surgical resection (SR) for newly oligometastatic breast cancer (NCT02364557). , 2022, Journal of Clinical Oncology.

[2]  G. Babiera,et al.  Early Local Therapy for the Primary Site in De Novo Stage IV Breast Cancer: Results of a Randomized Clinical Trial (EA2108) , 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  Sung-Bae Kim,et al.  Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study. , 2020, The Lancet. Oncology.

[4]  H. Rugo,et al.  De Novo Versus Recurrent HER2‐Positive Metastatic Breast Cancer: Patient Characteristics, Treatment, and Survival from the SystHERs Registry , 2019, The oncologist.

[5]  Michael Lock,et al.  Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-COMET): a randomised, phase 2, open-label trial , 2019, The Lancet.

[6]  Eric P. Winer,et al.  Breast Cancer Treatment: A Review , 2019, JAMA.

[7]  L. Pusztai,et al.  Long-Term Survival of De Novo Stage IV Human Epidermal Growth Receptor 2 (HER2) Positive Breast Cancers Treated with HER2-Targeted Therapy. , 2018, The oncologist.

[8]  I. Gibbs,et al.  Cost-Effectiveness of Pertuzumab in Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  G. Hortobagyi,et al.  Clinicopathological and surgical factors associated with long-term survival in patients with HER2-positive metastatic breast cancer , 2016, Breast Cancer Research and Treatment.

[10]  Sung-Bae Kim,et al.  Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer. , 2015, The New England journal of medicine.

[11]  F. Jänicke,et al.  Long-term tumor remission under trastuzumab treatment for HER2 positive metastatic breast cancer – results from the HER-OS patient registry , 2014, BMC Cancer.

[12]  E. Winer,et al.  Systemic therapy for patients with advanced human epidermal growth factor receptor 2-positive breast cancer: American Society of Clinical Oncology clinical practice guideline. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  H. Rugo,et al.  Long-term survivor characteristics in HER2-positive metastatic breast cancer from registHER , 2014, British Journal of Cancer.

[14]  C. Hudis,et al.  Cardiac dysfunction in the trastuzumab clinical trials experience. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  Ennis,et al.  Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. , 2001, The New England journal of medicine.

[16]  A. Shimomura,et al.  Durable complete response in HER2-positive breast cancer: a multicenter retrospective analysis , 2017, Breast Cancer Research and Treatment.

[17]  W. McGuire,et al.  Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. , 1987, Science.